文献速递临床免疫分子诊断

原型双联VIDAS免疫分析法检测HSV-1和HSV-2 IgG抗体的评估

Evaluation of a prototype biplex VIDAS immunoassay for type-specific detection of HSV-1 and HSV-2 IgG antibodies.
PubMed 文献 · J Clin Microbiol · 2026-09-30

该研究比较了原型VIDAS HSV 1&2 IgG双联免疫分析法与广泛使用的LIAISON HSV-1和HSV-2 IgG分析法,以蛋白质印迹法(WB)作为参考方法。共分析了501份血清样本,其中259例为PCR确诊的HSV-1或HSV-2感染患者。对于HSV-1 IgG,VIDAS的敏感性和特异性分别为95.4%和98.6%;对于HSV-2 IgG,敏感性为100%但特异性较低为90.7%。提高HSV-2阳性阈值可改善特异性。

要点

  • VIDAS原型检测HSV-1 IgG性能与LIAISON相当
  • HSV-2 IgG敏感性高但特异性较低,需优化阈值
  • 高HSV-1 IgG指数样本易出现HSV-2假阳性

核心结论

  • VIDAS原型检测HSV-1 IgG性能与LIAISON相当,而HSV-2 IgG特异性较低但可通过提高阈值改善。

研究设计与样本

  • 研究比较了VIDAS HSV 1&2 IgG原型检测与LIAISON HSV-1和HSV-2 IgG检测,以蛋白质印迹法(WB)作为参考方法。
  • 共分析了501份血清样本,来自348例患者,其中259例为PCR确诊的HSV-1或HSV-2感染患者。
  • 对两种检测结果不一致的89份样本进行了WB分析。

主要发现

  • 对于HSV-1 IgG检测,VIDAS原型检测的敏感性为95.4%,特异性为98.6%;LIAISON HSV-1 IgG检测的敏感性为98.9%,特异性为94.9%。
  • 对于HSV-2 IgG检测,VIDAS检测的敏感性为100%,特异性为90.7%;LIAISON HSV-2 IgG检测的敏感性为88.2%,特异性为99.4%。
  • 约30%的高HSV-1 IgG指数值样本在VIDAS检测中产生假阳性HSV-2 IgG结果。
  • ROC曲线分析表明,将VIDAS HSV-2阳性阈值从0.063提高至0.137,可将特异性提高至98.9%,同时保持敏感性为95.4%。

关键数值与推荐

  • HSV-1 IgG:VIDAS敏感性95.4%、特异性98.6%;LIAISON敏感性98.9%、特异性94.9%。
  • HSV-2 IgG:VIDAS敏感性100%、特异性90.7%;LIAISON敏感性88.2%、特异性99.4%。
  • VIDAS HSV-2阳性阈值从0.063提高至0.137时,特异性98.9%、敏感性95.4%。

临床怎么用

  • VIDAS原型检测可用于同时检测HSV-1和HSV-2 IgG抗体。
  • 对于HSV-2 IgG检测,需注意高HSV-1抗体水平样本的假阳性风险,必要时调整阳性阈值。
  • 在低流行人群中,优化HSV-2阳性阈值对提高特异性尤为重要。

局限性

  • 原始摘要未明确报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Type-specific serologic detection of IgG antibodies to herpes simplex virus (HSV)-1 and HSV-2 provides important diagnostic and epidemiological information. Novel assays are under development and require rigorous evaluation before routine clinical implementation. We compared the VIDAS HSV 1&2 IgG prototype assay (bioMérieux) with the widely used LIAISON HSV-1 and HSV-2 IgG assays (DiaSorin). Western blot (WB) analysis was used as the reference method to resolve discrepant results. A total of 501 serum samples from 348 patients were analyzed, including 259 patients with PCR-confirmed HSV-1 or HSV-2 infection. WB was performed on the 89 discordant samples between the two assays. For HSV-1 IgG detection, the VIDAS prototype assay showed a sensitivity of 95.4% and a specificity of 98.6%, compared with 98.9% and 94.9%, respectively, for the LIAISON HSV-1 IgG assay. For HSV-2 IgG, the VIDAS assay demonstrated a sensitivity of 100% but a lower specificity of 90.7%, whereas the LIAISON HSV-2 IgG assay showed a lower sensitivity of 88.2% and a higher specificity of 99.4%. Approximately 30% of the samples with high HSV-1 IgG index values yielded false-positive HSV-2 IgG results with the VIDAS assay. The receiver operating characteristic curve analysis indicated that increasing the VIDAS HSV-2 positivity threshold from 0.063 to 0.137 improved specificity to 98.9% while maintaining a sensitivity of 95.4%. For HSV-1 IgG detection, the VIDAS prototype assay showed performance comparable to that of the LIAISON assay. For HSV-2 IgG, optimization of the positivity threshold may substantially improve specificity, an important consideration in low-prevalence populations. IMPORTANCE: Type-specific serology is an important complement to molecular diagnosis of herpes simplex virus (HSV) infections, helping distinguish primary, recurrent, and non-primary infections; assess neonatal transmission risk; and support patient counseling. Because western blot, the reference method, is not routinely available, the clinical value of HSV serology relies on the performance of automated immunoassays. We evaluated a novel VIDAS HSV 1&2 IgG biplex prototype assay and compared it with a widely used commercial assay. The VIDAS assay showed performance comparable to the LIAISON assay for HSV-1 IgG detection while offering simultaneous detection of HSV-1 and HSV-2 antibodies in a single test. For HSV-2 IgG, however, false-positive results were observed, particularly in samples with high HSV-1 antibody levels. Importantly, optimizing the HSV-2 positivity threshold improved specificity while maintaining high sensitivity. These findings provide data for assay optimization before commercialization and highlight the need to balance sensitivity and specificity for accurate clinical interpretation.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Roccon M, Charly H, Truffot A, et al. Evaluation of a prototype biplex VIDAS immunoassay for type-specific detection of HSV-1 and HSV-2 IgG antibodies. J Clin Microbiol. 2026. PMID: 42813787. doi:10.1128/jcm.00931-26

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。